Search

Current clinical indicators for assessing liver/kidney injury are functional rather than injury indicators, which may cause some delays in the diagnosis of drug-induced liver injury (DILI) and kidney injury (DIKI). Therefore, the development of noninvasive and real-time methods for the effective diagnosis of DILI/DIKI is of great benefit to their clinical management. Herein, we constructed a dicyanoisophorone-based near-infrared (NIR) fluorescent probe (PNDP). Upon the addition of ONOO−, the probe exhibits 111.4-fold fluorescence enhancement at 665 nm with a large Stokes shift of 175 nm as well as excellent selectivity, strong anti-interference capability, and a low limit of detection (118.9 nmol L−1). More significantly, the PNDP was successfully employed for the sensitive detection of ONOO− in living cells and DILI/DIKI mice models. In vitro and in vivo bioimaging experiments demonstrated that the PNDP has greater versatility and promising potential for use as a diagnostic agent for the diagnosis of drug-induced hepatotoxicity and nephrotoxicity by monitoring ONOO− fluctuations. [ABSTRACT FROM AUTHOR]

Black phosphorus nanomaterials (BPN) have been well developed in tumor therapy. However, lack of diagnostic function limits the development of BPN in biomedicine. Lanthanide-doped nanoparticles are considered as versatile materials for fluorescence or magnetic resonance imaging. Integration of BPN with lanthanide-doped nanoparticles was rarely reported owing to the complex synthesis processes and poor modification effect. Herein, we report a simple and general method for synthesizing BPN@NaReF4 (Re: Gd or Y, Yb, Er) nanocomposite. TEM and XRD characterization confirm efficient combination of BPN and NaGdF4 or NaYF4:Yb,Er (18.2 mol %) after one-step mixing. The FTIR and XPS spectra were used to prove the generation of PO43−-Gd and P-Gd coordination bonds and clarify ligand exchange mechanism. The anchored nanoparticles on BPN were stable and become hydrophilic. The prepared BPN@NaGdF4 exhibit the signals of photoacoustic and magnetic resonance imaging. The obtained BPN@NaYF4:Yb,Er (18.2 mol %) have the potential in fluorescence bioimaging. We believe that this work will expand the applications of BPN in diagnosis and therapy together. [ABSTRACT FROM AUTHOR]

Current clinical indicators for assessing liver/kidney injury are functional rather than injury indicators, which may cause some delays in the diagnosis of drug-induced liver injury (DILI) and kidney injury (DIKI). Therefore, the development of noninvasive and real-time methods for the effective diagnosis of DILI/DIKI is of great benefit to their clinical management. Herein, we constructed a dicyanoisophorone-based near-infrared (NIR) fluorescent probe (PNDP). Upon the addition of ONOO - , the probe exhibits 111.4-fold fluorescence enhancement at 665 nm with a large Stokes shift of 175 nm as well as excellent selectivity, strong anti-interference capability, and a low limit of detection (118.9 nmol L -1 ). More significantly, the PNDP was successfully employed for the sensitive detection of ONOO - in living cells and DILI/DIKI mice models. In vitro and in vivo bioimaging experiments demonstrated that the PNDP has greater versatility and promising potential for use as a diagnostic agent for the diagnosis of drug-induced hepatotoxicity and nephrotoxicity by monitoring ONOO - fluctuations.

Patients diagnosed with pancreatic cancer at a late stage have a dismal survival rate. Accurate early detection of pancreatic cancer with a size of 10 mm or less could dramatically improve patient survival after timely treatments. We have developed a new PET probe ZD2-( 68 Ga-NOTA) specific to extradomain-B fibronectin (EDB-FN), an oncoprotein in tumor microenvironment, for sensitive molecular imaging and early diagnosis of pancreatic cancer. A targeted ligand ZD2-NOTA is synthesized by conjugation of a macrocyclic ligand NOTA via a 6-aminohexanoic acid spacer to a linear ZD2 peptide (Thr-Val-Arg-Thr-Ser-Ala-Asp). ZD2-( 68 Ga-NOTA) is synthesized by relabeling of ZD2-NOTA with 68 GaCl 3 in a high purity under GMP conditions. The expression of EDB-FN is demonstrated in BxPC3 and Capan-1 human pancreatic cancer cells and tumor xenografts in mice. ZD2-( 68 Ga-NOTA) results in significantly higher uptake in the both BxPC3 and Capan-1 tumor xenografts than normal organs and tissues, including the brain, heart, liver and muscle, at 1 hr postinjection in mice. The tumor to muscle uptake ratio is at least 5 folds for the tracer in both tumors. ZD2-( 68 Ga-NOTA) is able to clearly delineate the PaCa tumors with a size of 10 mm or less with minimal background noise in normal tissues, including the liver. Substantial tumor uptake is still visible at 2 hr post-injection. The results suggest that the ZD2 peptide targeted PET probe has a potential for sensitive molecular imaging of EDB-FN and early detection of pancreatic cancer to improve healthcare of the patients diagnosed with the disease., Competing Interests: None., (AJNMMI Copyright © 2019.)